Genomic profiling of human tumors: moving from cytogenetics to DNA arrays

被引:0
|
作者
Theillet, C
Orsetti, B
Redon, R
du Manoir, S
机构
[1] CRLC, Ctr Rech, CNRS, UMR 5535, F-34298 Montpellier 5, France
[2] ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch, France
关键词
genome; hybridization;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic instability results, in a large majority of solid tumors, in deep chromosomal rearrangements. However, because chromosomal instability produces highly complex caryotypes, rarely showing stereotypic aberrations, it has not been possible to characterize solid cancers according to specific patterns of chromosomal rearrangements. This contracts with the situation in hematological malignancies, where cytogenetics has allowed to lay out the basis of a renewed classification. New insights have been brought by the development of comparative genomic hybridization (CGH). This molecular cytogenetics approach was originally devised to detect regions in the genome of tumor cells undergoing quantitative changes, i.e. gains or losses of copy numbers. The large body of studies based on CGH show that solid tumors undergo frequent gains and losses and that every chromosomes shaw at least one region of anomaly. Furthermore, different tumor types present distinct CGH patterns of gains and losses. These observations favor the idea that it may be possible to type human solid cancers according to their patterns of genomic aberrations. However; despite the fact that a number of CGH based studies present data suggesting that different tumor types or cancers at different stages of evolution show distinct patterns of gains and losses, it has proven difficult to be conclusive. This can be mainly attributed to the lack of spatial resolution of CGH. indeed CGH uses metaphase chromosomes as hybridization targets and therefore its resolution is at the level of chromosomal banding. The recent adaptation of DNA array technology to CGH will allow to pass this limitation. In DNA array based CGH (array-CGH) metaphase chromosomes have been replaced by spots of cloned DNA. These DNA clones may either be genomic (BACs, YACs or cosmids) or coding (cDNAs). The resolution of array-CGH is therefore determined by the size of the cloned DNA insert (100 Kb for BACs, 1-2 kb for cDNAs). Data corresponding to each of these clones is or will be in a near future linked to DNA sequence data. Hence, in a near future, array-CGH will allow to increase the resolution from a cytogenetic level to a molecular level. Finally, because array technology is highly adaptable to automation, going am classical CGH to array-CGH will produce a quantum leap in throughput.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 50 条
  • [31] Expression profiling: DNA arrays in many guises
    Granjeaud, S
    Bertucci, F
    Jordan, BR
    BIOESSAYS, 1999, 21 (09) : 781 - 790
  • [32] GENOMIC SEQUENCING OF HUMAN TUMORS - ADVANTAGES AND PITFALLS OF USE OF AN AUTOMATED DNA SEQUENCER
    WILKE, W
    ROBINSON, R
    LABORATORY INVESTIGATION, 1992, 66 (01) : A122 - A122
  • [33] Clinical Utility of Genomic Profiling of Pancreatic Neuroendocrine Tumors
    Demeure, Michael J.
    Evers, Lisa
    Lenkiewicz, Elizabeth
    Holley, Tara
    Bubendorf, Lukas
    Ruiz, Christian
    Bussey, Kimberly J.
    Barrett, Michael T.
    PANCREAS, 2011, 40 (02) : 326 - 327
  • [34] GENOMIC PROFILING OF PEDIATRIC TUMORS: A SINGLE INSTITUTION EXPERIENCE
    Swilling, Aubrey
    Pham, Robin
    Hamby, Tyler
    Ray, Anish
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S96 - S96
  • [35] Comprehensive genomic profiling to identify gene alterations in DNA repair pathway across solid tumors.
    McDonnell, Kevin
    Basu, Gargi D.
    Hoag, Jess W.
    Hall, David W.
    Alyaqoub, Fadel S.
    Dombrowski, Susan M.
    Noel, Pawan
    Szelinger, Szabolcs
    Udhane, Sameer S.
    Wang, Min
    LoBello, Janine R.
    Thakkar, Snehal Govind
    Baehner, Frederick L.
    Hong, Christine
    Park, Wai
    Idos, Gregory
    Gray, Stacy W.
    Gruber, Stephen B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Comprehensive genomic profiling of malignant phyllodes tumors of the breast
    Sahar Nozad
    Christine E. Sheehan
    Laurie M. Gay
    Julia A. Elvin
    Jo-Anne Vergilio
    James Suh
    Shakti Ramkissoon
    Alexa B. Schrock
    Kim M. Hirshfield
    Nadia Ali
    Shridar Ganesan
    Siraj M. Ali
    Vincent A. Miller
    Philip J. Stephens
    Jeffrey S. Ross
    Jon H. Chung
    Breast Cancer Research and Treatment, 2017, 162 : 597 - 602
  • [37] Comprehensive genomic profiling of malignant phyllodes tumors of the breast
    Nozad, Sahar
    Sheehan, Christine E.
    Gay, Laurie M.
    Elvin, Julia A.
    Vergilio, Jo-Anne
    Suh, James
    Ramkissoon, Shakti
    Schrock, Alexa B.
    Hirshfield, Kim M.
    Ali, Nadia
    Ganesan, Shridar
    Ali, Siraj M.
    Miller, Vincent A.
    Stephens, Philip J.
    Ross, Jeffrey S.
    Chung, Jon H.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 162 (03) : 597 - 602
  • [38] From human cytogenetics to human chromosomics
    Liehr, T.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1904 - 1905
  • [39] Comprehensive genomic and transcriptomic profiling of gastrointestinal stromal tumors
    Horak, Peter
    Hajnic, Matea
    Gieldon, Laura
    Hlevnjak, Mario
    Richter, Susan
    Flutter, Barbara
    Falkenhorst, Johanna
    Uhrig, Sebastian
    Warsow, Gregor
    Paramasivam, Nagarajan
    Groeschel, Stefan
    Klink, Barbara
    Kreutzfeldt, Simon
    Heining, Christoph
    Heilig, Christoph E.
    Froehlich, Martina
    Richter, Stephan
    Brandts, Christian
    Weichert, Wilko
    Jost, Philipp
    Neumann, Olaf
    Zapatka, Marc
    Stenzinger, Albrecht
    Marx, Alexander
    Brors, Benedikt
    Schroeck, Evelin
    Bauer, Sebastian
    Hohenberger, Peter
    Glimm, Hanno
    Scholl, Claudia
    Froehling, Stefan
    CANCER RESEARCH, 2019, 79 (13)
  • [40] Genomic profiling of esophagogastric (EG) tumors in clinical practice
    Riches, Jamie Cathleen
    Schultz, Nikolaus
    Ku, Geoffrey Yuyat
    Imtiaz, Tooba
    Kelsen, David Paul
    Ilson, David H.
    Solit, David B.
    Berger, Michael F.
    Ladanyi, Marc
    Arcila, Maria E.
    Vakiani, Efsevia
    Janjigian, Yelena Yuriy
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)